Video

Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami

Author(s):

CURE Media Group

View the full CURE® Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami on demand.

Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of doctor with grey hair.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Related Content
Image of lung.
March 31st 2025

COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer

Spencer Feldman
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Illustration of cells.
March 27th 2025

Quadruplet Regimen Preferable to Triplets in Multiple Myeloma

Alex Biese
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of woman with pink ribbon.
March 20th 2025

Evolving Treatments and Advances in HER2-Positive Breast Cancer

Ryan Scott
Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky: © Konstanin Yuganov - stock.adobe.com.
March 20th 2025

What Patients With Breast Cancer Need to Know About Itovebi

Alex Biese
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.